Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Characterizing the blood stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum.
Int J Antimicrob Agents. 2024 May 9:107196. doi: 10.1016/j.ijantimicag.2024.107196. Online ahead of print.
Int J Antimicrob Agents. 2024.
PMID: 38734217
Free article.
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, McCallum Pardey TG, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM; Novavax 2019nCoV-311 Study Group.
Bennett C, et al.
Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077-X. doi: 10.1016/S1473-3099(24)00077-X. Online ahead of print.
Lancet Infect Dis. 2024.
PMID: 38460525
Item in Clipboard
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
Baker B, Bermingham IM, Leelasena I, Hickling J, Young PR, Muller DA, Forster AH.
Baker B, et al. Among authors: leelasena i.
Vaccines (Basel). 2023 Nov 17;11(11):1725. doi: 10.3390/vaccines11111725.
Vaccines (Basel). 2023.
PMID: 38006057
Free PMC article.
Item in Clipboard
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Polasek TM, Leelasena I, Betscheider I, Marolt M, Kohlhof H, Vitt D, Fliegert F, Muehler AR.
Polasek TM, et al. Among authors: leelasena i.
Clin Pharmacol Drug Dev. 2023 May;12(5):525-534. doi: 10.1002/cpdd.1243. Epub 2023 Mar 20.
Clin Pharmacol Drug Dev. 2023.
PMID: 36938862
Clinical Trial.
Item in Clipboard
Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Barber BE, Abd-Rahman AN, Webster R, Potter AJ, Llewellyn S, Marquart L, Sahai N, Leelasena I, Birrell GW, Edstein MD, Shanks GD, Wesche D, Moehrle JJ, McCarthy JS.
Barber BE, et al. Among authors: leelasena i.
Clin Infect Dis. 2023 Jun 8;76(11):1919-1927. doi: 10.1093/cid/ciad075.
Clin Infect Dis. 2023.
PMID: 36795050
Free PMC article.
Item in Clipboard
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, McFall H, Robinson M, Plested JS, Zhu M, Cloney-Clark S, Zhou B, Chau G, Robertson A, Maciejewski S, Hammond HL, Baracco L, Logue J, Frieman MB, Smith G, Patel N, Glenn GM; Novavax 2019nCoV101 Study Group.
Mallory RM, et al.
Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
Lancet Infect Dis. 2022.
PMID: 35963274
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite